This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Robinson, C. A. Articles by Kuhn, R. J. Search for Related Content Social Bookmarking                         What's this?

Management of Pulmonary Disease in Patients with Cystic Fibrosis

University of Kentucky Chandler Medical Center, Department of Pharmacy, 800 Rose Street, C117, Lexington, KY 40536-0293

Robert J. Kuhn

University of Kentucky Chandler Medical Center, Department of Pharmacy, 800 Rose Street, C117, Lexington, KY 40536-0293, rjkuhn1{at}pop.uky.edu

Cystic fibrosis is the most common, life-shortening autosomal recessive disease, affecting approximately 1 in 3400 live births in the United States. Gastrointestinal and pulmonary manifestations are most common. With the introduction of pancreatic enzyme and vitamin supplementation, lung disease accounts for the vast majority of morbidity and mortality in patients with cystic fibrosis. The lungs of cystic fibrosis patients are essentially normal at birth but demonstrate evidence of airway inflammation and infection in early infancy. A vicious cycle of inflammation, infection and obstruction ultimately leads to destruction of airways, impairment of gas exchange and death.

Current pharmacological management of pulmonary disease targets reducing airway obstruction, controlling infection and more recently, controlling inflammation. An increased recovery of unusual and highly resistant bacteria from patients with more advanced disease has been observed. Aggressive treatment of acute pulmonary exacerbations with combination antibiotic therapy for two to three weeks has shown pronounced beneficial effects. The routine use of prophylactic antistaphylococcal antibiotics is still controversial.

Although current pharmacologic treatment is symptomatic, new agents are being developed and studied that target the underlying defect in the CFTR protein. This review focuses on current pharmacologic management of pulmonary disease in patients with cystic fibrosis and the role of new agents emerging for the treatment of this disease.

Key Words: cystic fibrosis • aerosolized antibiotics • inhaled antibiotics • antibiotics • pancreatic enzymes • bronchodilators • acetylcysteine • dornase alfa • pharmacokinetics • corticosteroids • ibuprofen • macrolides • gene therapy

Journal of Pharmacy Practice, Vol. 14, No. 3, 207-227 (2001)
DOI: 10.1106/4WVW-ACLD-EKV6-MBJJ


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?